{"id":416153,"date":"2021-01-18T19:34:18","date_gmt":"2021-01-19T00:34:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416153"},"modified":"2021-01-18T19:34:18","modified_gmt":"2021-01-19T00:34:18","slug":"propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/","title":{"rendered":"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients"},"content":{"rendered":"

<\/p>\n

Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients<\/b><\/p>\n

MELBOURNE, Australia–(BUSINESS WIRE<\/a>)–Propanc Biopharma, Inc.<\/a><\/b><\/span> (OTC: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by Drs Natalia Luque Caro and Fernando G\u00e1lvez Montosa, medical oncologists specializing in pancreatic and ovarian cancers, respectively, from the University Hospital of Ja\u00e9n, in Granada, Spain. The evaluation will most likely be conducted as separate Phase IIa proof of concept (POC), multi-trial center studies for each target indication.\n<\/p>\n

\nThe expressions of interest were confirmed after evaluation of Propanc\u2019s scientific literature supporting the use of proenzymes in pancreatic and ovarian cancers. The Phase IIa POC studies will be conducted after a Phase Ib dose escalation study evaluating the tolerability and activity of proenzyme therapy in patients with advanced solid tumors is completed, planned for 2021, at the Peter Mac Cancer Center, Melbourne, Australia.\n<\/p>\n

\n\u201cReceiving expressions of interest from Drs Caro and Montoya at the University Hospital of Ja\u00e9n provides important infrastructure to plan our multi-trial center studies, which will likely require up to 60 patients for each study in pancreatic and ovarian cancers, which is why we were thinking of running these trials in Europe, due to the larger patient populations,\u201d said James Nathanielsz, Propanc\u2019s Chief Executive Officer. \u201cBy running multi-trial centre studies for our Phase IIa studies, we ensure that we have sufficient numbers to complete the trials more efficiently than if we ran the trials in Australia, alone. Furthermore, the University Hospital of Ja\u00e9n is located in Granada, Spain, and is a well-known biopharmaceutical hub with a strong reputation among multi-national companies. We look forward to a potential collaboration with the clinical trial investigators from this reputable institution.\u201d\n<\/p>\n

About Propanc Biopharma, Inc.<\/b><\/p>\n

\nPropanc Biopharma, Inc. (the \u201cCompany\u201d) is developing a novel cell differentiation therapy using pancreatic proenzymes that target and eradicate cancer stem cells to prevent recurrence and metastasis of solid tumors in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com<\/a>.\n<\/p>\n

\nThe Company\u2019s novel cell differentiation therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body\u2019s primary defense against cancer.\n<\/p>\n

\nTo view the Company\u2019s \u201cMechanism of Action\u201d video on its anti-cancer lead product candidate, PRP, please click on the following link: http:\/\/www.propanc.com\/news-media\/video<\/a><\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nAll statements other than statements of historical facts contained in this press release are \u201cforward-looking statements,\u201d which may often, but not always, be identified by the use of such words as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cwill likely result,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201ccontinue,\u201d \u201ctarget\u201d or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company\u2019s ability to continue as a going concern absent new debt or equity financings; the Company\u2019s current reliance on substantial debt financing that it is unable to repay in cash; the Company\u2019s ability to successfully remediate material weaknesses in its internal controls; the Company\u2019s ability to reach research and development milestones as planned and within proposed budgets; the Company\u2019s ability to control costs; the Company\u2019s ability to obtain adequate new financing on reasonable terms; the Company\u2019s ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Company\u2019s ability to obtain and maintain patent protection; the Company\u2019s ability to recruit employees and directors with accounting and finance expertise; the Company\u2019s dependence on third parties for services; the Company\u2019s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company\u2019s Registration Statement on Form S-1, Amendment No. 5, filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) on November 3, 2020, and in the Company\u2019s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210118005099\/en\/<\/a><\/span><\/p>\n

Investor Relations and Media Contacts:
\n<\/b>
Mr. James Nathanielsz
\n
Propanc Biopharma, Inc.
\n
irteam@propanc.com
\n<\/a>
+61-3-9882-0780\n<\/p>\n

KEYWORDS:<\/b> Australia\/Oceania Europe Australia Spain<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research General Health Pharmaceutical Oncology Hospitals Genetics Clinical Trials Science Surgery Biotechnology FDA Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by Drs Natalia Luque Caro and Fernando G\u00e1lvez Montosa, medical oncologists specializing in pancreatic and ovarian cancers, respectively, from the University Hospital of Ja\u00e9n, in Granada, Spain. The evaluation will most likely be conducted as separate Phase IIa proof of concept (POC), … <\/p>\n

Continue reading “Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416153","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPropanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by Drs Natalia Luque Caro and Fernando G\u00e1lvez Montosa, medical oncologists specializing in pancreatic and ovarian cancers, respectively, from the University Hospital of Ja\u00e9n, in Granada, Spain. The evaluation will most likely be conducted as separate Phase IIa proof of concept (POC), … Continue reading "Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T00:34:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients\",\"datePublished\":\"2021-01-19T00:34:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/\"},\"wordCount\":859,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/\",\"name\":\"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-19T00:34:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/","og_locale":"en_US","og_type":"article","og_title":"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients - Market Newsdesk","og_description":"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by Drs Natalia Luque Caro and Fernando G\u00e1lvez Montosa, medical oncologists specializing in pancreatic and ovarian cancers, respectively, from the University Hospital of Ja\u00e9n, in Granada, Spain. The evaluation will most likely be conducted as separate Phase IIa proof of concept (POC), … Continue reading \"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T00:34:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients","datePublished":"2021-01-19T00:34:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/"},"wordCount":859,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/","name":"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-19T00:34:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005099r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-receives-expression-of-interest-to-evaluate-proenzyme-therapy-in-pancreatic-and-ovarian-cancer-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416153"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416153\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}